Hyperliquid Strategies Inc (PURR) Stock Price, Quote & News

Company Profile

Hyperliquid Strategies Inc. operates as a digital asset treasury company focused on the blockchain and cryptocurrency sector. The company provides investors exposure to the HYPE token through treasury management strategies, such as token accumulation, staking, and yield optimization within the Hyperliquid ecosystem. The company was incorporated in 2025 and is based in New York, New York.

Industry: Capital Markets

Sector: Financial Services

Phone: 212 883 4330

Website: www.hypestrat.xyz

Address:

477 Madison Avenue, 22nd Floor, New York, United States

luminouslumens Aug. 25 at 1:21 AM

$PURR $XHLD $USDE.X $FRMI

0 · Reply

De12 Aug. 25 at 1:04 AM

$CAPR $PURR $IOVA Want some Green tomorrow!!

0 · Reply

DogDayDreaming Aug. 25 at 12:56 AM

$PURR Options positioning on Friday's $15 strike generated unusual trading in the last two days, sufficient to generate a briefing.com report. I ran the numbers through SuperGrok, and also took a look at analyst estimates, and methadology issues (how they make assumptions on $HYPE.X that drive the wide range in estimates). Something to chew on vs. typical Stocktwits grub: https://grok.com/share/c2hhcmQtNA_aeb440de-211c-422a-a304-553f009e9d07

0 · Reply

Mardukas Aug. 25 at 12:48 AM

$PURR hold on to your butts

0 · Reply

Hammer123 Aug. 24 at 11:54 PM

$PURR $HYPE.X $PURR

0 · Reply

DoubleETrader Aug. 24 at 9:50 PM

$PURR If your in below $9 you got it at a discount. QQQ sold off today. PURR ended slightly green. Price action looks like consolidation between $10-$11. There’s more to come this week I’m sure.

0 · Reply

Makeittrades Aug. 24 at 8:48 PM

$PURR the company generatwd over a billion in cashflow with just over 11 employees. Wallstreet craves free cashflow, hold on to youkr shares and accumulate.

1 · Reply

NewNewOld Aug. 24 at 8:46 PM

$PURR er 27th of august and options expiration day next say 28th of august.

0 · Reply

Therow Aug. 24 at 8:42 PM

$CYPH $ZEC.X $HYPE.X $PURR Friday was just the beginning. Now consolidating for round two. Don’t skip the dip! You’d be fading this money.

0 · Reply

The_Great_Gatsbear Aug. 24 at 8:36 PM

$PURR I see $HYPE.X going to $250-$300 within the next 6 months, And in that same time I expect $PURR to go to $40-$50

0 · Reply

Trump suggests possibility of regulating Hyperliquid, CNBC reports

CBOE CME MIAX

Aug 19, 2026, 4:15 PM EDT - 5 days ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Fiscal Year Ended June 30, 2026

Jul 21, 2026, 8:00 AM EDT - 4 weeks ago

Hyperliquid Strategies Registration statement: Registration filing

Jul 8, 2026, 8:30 AM EDT - 6 weeks ago

Defiance Launches PUR: The First 2X Long PURR ETF

PUR

2026-07-01T19:50:11.000Z - 7 weeks ago

Hyperliquid Strategies management to meet with Oppenheimer

2026-06-29T20:20:21.000Z - 2 months ago

Hyperliquid Strategies to be added to Russell 3000, 2000, S&P Global BMI Indices

Jun 29, 2026, 4:15 PM EDT - 2 months ago

Hyperliquid Strategies Inc Added to the Russell 3000, Russell 2000 and S&P Global BMI Indices

Jun 25, 2026, 8:00 AM EDT - 2 months ago

Hyperliquid Strategies Registration statement: Registration filing

Jun 16, 2026, 9:00 AM EDT - 2 months ago

Hyperliquid Strategies Inc Relaunches Website with Expanded Analytics, HYPE Tokenomics and Insights Sections

Jun 16, 2026, 8:00 AM EDT - 2 months ago

Hyperliquid Strategies Registration statement: Registration filing

Jun 4, 2026, 5:46 PM EDT - 2 months ago

Hyperliquid Strategies CEO on why he thinks banks are undervaluing SpaceX's IPO

SPCX

May 22, 2026, 8:00 AM EDT - 3 months ago

Hyperliquid Strategies Registration statement: Registration filing

2026-05-22T10:05:07.000Z - 3 months ago

Hyperliquid Strategies files to sell 35.16M shares of common stock for holders

2026-05-11T12:53:34.000Z - 3 months ago

Hyperliquid Strategies price target raised to $8 from $6 at Cantor Fitzgerald

May 7, 2026, 5:00 PM EDT - 3 months ago

Hyperliquid Strategies Earnings Call Transcript: Q3 2026

May 7, 2026, 5:00 PM EDT - 3 months ago

Hyperliquid Strategies Slides: Q3 2026

May 7, 2026, 5:00 PM EDT - 3 months ago

Hyperliquid Strategies Quarterly report: Q3 2026

May 7, 2026, 5:00 PM EDT - 3 months ago

Hyperliquid Strategies Earnings release: Q3 2026

May 7, 2026, 4:15 PM EDT - 3 months ago

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended March 31, 2026

May 7, 2026, 4:15 PM EDT - 3 months ago

Hyperliquid Strategies and Unit Labs Announce Validator on Hyperliquid

Apr 28, 2026, 4:15 PM EDT - 4 months ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Fiscal Quarter Ended March 31, 2026

Mar 24, 2026, 4:15 PM EDT - 5 months ago

Hyperliquid Strategies Inc. Announces Milestone with Launch of Options Trading on PURR Common Stock

Feb 16, 2026, 7:00 AM EST - 6 months ago

Hyperliquid Strategies Slides: Corporate presentation

Feb 11, 2026, 8:00 AM EST - 6 months ago

Hyperliquid Strategies Earnings Call Transcript: Q2 2026

Feb 11, 2026, 8:00 AM EST - 6 months ago

Hyperliquid Strategies Quarterly report: Q2 2026

Feb 11, 2026, 8:00 AM EST - 6 months ago

Hyperliquid Strategies Earnings release: Q2 2026

Feb 11, 2026, 8:00 AM EST - 6 months ago

Hyperliquid Strategies Slides: Q2 2026

Feb 11, 2026, 6:45 AM EST - 6 months ago

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended December 31, 2025

Feb 5, 2026, 4:15 PM EST - 7 months ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Quarter Ended December 31, 2025

Dec 8, 2025, 9:20 AM EST - 9 months ago

Hyperliquid Strategies Inc Announces $30 million Stock Repurchase Program

Dec 3, 2025, 5:45 PM EST - 9 months ago

Ex-Barclays CEO unpacks Hyperliquid: ‘The FUTURE of finance'

Dec 2, 2025, 4:30 PM EST - 9 months ago

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Nov 18, 2025, 9:00 AM EST - 9 months ago

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

Nov 12, 2025, 7:00 AM EST - 10 months ago

Hyperliquid Strategies Slides: Investor presentation

Oct 22, 2025, 8:00 AM EDT - 10 months ago

Hyperliquid Strategies Registration statement: Registration Filing

Oct 15, 2025, 10:03 AM EDT - 11 months ago

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma

Sep 19, 2025, 9:00 AM EDT - 1 year ago

Sonnet to Present at the MedInvest Biotech & Pharma Conference

Aug 11, 2025, 9:15 AM EDT - 1 year ago

Sonnet Releases Virtual Investor "What This Means" Segment

Aug 4, 2025, 8:40 AM EDT - 1 year ago

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Jul 14, 2025, 6:00 AM EDT - 1 year ago

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

May 1, 2025, 9:00 AM EDT - 1 year ago

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Apr 4, 2025, 9:00 AM EDT - 1 year ago

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Apr 1, 2025, 4:15 PM EDT - 1 year ago

Sonnet Announces Release of Corporate Update Video

Apr 1, 2025, 7:30 AM EDT - 1 year ago

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Mar 26, 2025, 9:05 AM EDT - 1 year ago

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Mar 19, 2025, 8:50 AM EDT - 1 year ago

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Mar 11, 2025, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 26, 2025, 9:00 AM EST - 1 year ago

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Feb 19, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Feb 18, 2025, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Feb 13, 2025, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Feb 13, 2025, 8:00 AM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Jan 28, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Jan 22, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 21, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Dec 23, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Dec 17, 2024, 8:50 AM EST - 1 year ago

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Dec 9, 2024, 3:42 PM EST - 1 year ago

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2024, 8:45 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Dec 4, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Nov 12, 2024, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Nov 6, 2024, 1:20 PM EST - 1 year ago

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Nov 6, 2024, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Oct 17, 2024, 8:45 AM EDT - 2 years ago

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Oct 9, 2024, 8:45 AM EDT - 2 years ago

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Oct 4, 2024, 8:30 AM EDT - 2 years ago

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

luminouslumens Aug. 25 at 1:21 AM

$PURR $XHLD $USDE.X $FRMI

0 · Reply

De12 Aug. 25 at 1:04 AM

$CAPR $PURR $IOVA Want some Green tomorrow!!

0 · Reply

DogDayDreaming Aug. 25 at 12:56 AM

0 · Reply

Mardukas Aug. 25 at 12:48 AM

$PURR hold on to your butts

0 · Reply

Hammer123 Aug. 24 at 11:54 PM

$PURR $HYPE.X $PURR

0 · Reply

DoubleETrader Aug. 24 at 9:50 PM

$PURR If your in below $9 you got it at a discount. QQQ sold off today. PURR ended slightly green. Price action looks like consolidation between $10-$11. There’s more to come this week I’m sure.

0 · Reply

Makeittrades Aug. 24 at 8:48 PM

$PURR the company generatwd over a billion in cashflow with just over 11 employees. Wallstreet craves free cashflow, hold on to youkr shares and accumulate.

1 · Reply

NewNewOld Aug. 24 at 8:46 PM

$PURR er 27th of august and options expiration day next say 28th of august.

0 · Reply

Therow Aug. 24 at 8:42 PM

$CYPH $ZEC.X $HYPE.X $PURR Friday was just the beginning. Now consolidating for round two. Don’t skip the dip! You’d be fading this money.

0 · Reply

The_Great_Gatsbear Aug. 24 at 8:36 PM

$PURR I see $HYPE.X going to $250-$300 within the next 6 months, And in that same time I expect $PURR to go to $40-$50

0 · Reply

im_ichiban Aug. 24 at 8:20 PM

$YSS break above $10.4 squeeze coming be patient $PURR $SNDK $SPCX

0 · Reply

NewNewOld Aug. 24 at 8:06 PM

$PURR ofcourse this start to feel interesting when have done dd. Hyperliquid mcap 20billion and this 2billion. Have to follow.

0 · Reply

im_ichiban Aug. 24 at 7:59 PM

$YSS time for a short squeeze $PURR $SPCX $MRNA

0 · Reply

NewNewOld Aug. 24 at 7:53 PM

$PURR Hyperliquid price 82 to 77,5

2 · Reply

NewNewOld Aug. 24 at 7:25 PM

$PURR purr makes middle finger daily chart

0 · Reply

lucyan1988 Aug. 24 at 7:22 PM

$PURR oh my, i thought we were supposed at 20s?

2 · Reply

BBW69 Aug. 24 at 6:51 PM

$PURR

0 · Reply

vu_jade Aug. 24 at 6:35 PM

$HYPE.X Here comes The dip to add .. $PURR

0 · Reply

Jackie_Treehorn Aug. 24 at 6:35 PM

$PURR interesting to see what happens with earnings Thursday and short interest increasing.

0 · Reply

yosheungmin Aug. 24 at 6:24 PM

$PURR Top institutional holders

0 · Reply

1234counting Aug. 24 at 6:05 PM

$PURR it seems tk go up in ah or pr and then down during the day?

1 · Reply

NewNewOld Aug. 24 at 5:31 PM

$PURR 2 dollar end of the week

2 · Reply

Market Cap	1.53B
Revenue (ttm)	1.00M
Net Income (ttm)	-16.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	4.80
Profit Margin	-1,601.00%
Debt to Equity Ratio	0.00

Volume	28,387,998
Avg Vol	12,993,840
Day's Range	N/A - N/A
Shares Out	144.45M
Stochastic %K	85%
Beta	1.71
Analysts	Strong Sell
Price Target	$13.05